Oncolytic Poxvirus CD19 Expression for Solid Tumor CAR T Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oncolytic viruses used in cancer treatment have limited clinical benefits and safety concerns, necessitating the development of more potent and safe oncolytic viruses with enhanced anti-tumor potency.
Innovation Solution
Development of recombinant chimeric poxviruses with a nucleotide sequence identity of at least 70% to SEQ ID NO: 1 or SEQ ID NO: 2, modified to delete the TK gene and encode human CD19, which can infect and express CD19 on cancer cells, making them susceptible to CD19 CAR T cells for targeted killing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If highly attenuated oncolytic viruses are used to ensure safety, then safety is improved, but anti-tumor potency is worsened
Solution Approach 1:
The virus therapy is segmented into two distinct components: a highly attenuated oncolytic virus (providing safety) that delivers a transgene encoding CD19, and CD19 CAR T cells (providing potent anti-tumor activity). This segmentation allows each component to optimize for its specific function without compromising the other, resolving the contradiction between safety and anti-tumor potency.
Solution Approach 2:
The oncolytic virus acts as an intermediary vehicle that transfers the CD19 transgene into cancer cells, enabling subsequent recognition and destruction by CD19 CAR T cells. This intermediary approach allows the attenuated virus to safely deliver therapeutic cargo while the CAR T cells provide the potent killing function, separating safety and potency functions.
2Ease of operation
If oncolytic viruses are used as stand-alone treatments, then ease of operation is improved, but clinical benefits are worsened
Solution Approach 1:
The invention merges two therapeutic modalities (oncolytic virus therapy and CAR T cell therapy) into a combination treatment regimen. The oncolytic virus first infects and kills cancer cells while delivering CD19 transgene, and the CD19 CAR T cells subsequently recognize and destroy the now-vulnerable cells. This merging produces synergistic clinical benefits greater than either treatment alone, while maintaining relative ease of administration through sequential or simultaneous delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant chimeric poxviruses demonstrate superior cancer cell killing capabilities and can effectively activate CD19 CAR T cells to enhance cancer treatment efficacy, particularly in B-cell cancers.
Implementation Method 1
Oncolytic viruses are naturally occurring or genetically modified viruses that infect, replicate in, and eventually kill cancer cells while leaving healthy cells unharmed
Implementation Method 2
The recombinant chimeric poxviruses demonstrate superior cancer cell killing capabilities and can effectively activate CD19 CAR T cells to enhance cancer treatment efficacy
Implementation Method 3
further comprising a nucleotide sequence encoding human CD19 or a portion thereof. The recombinant poxvirus is oncolytic and can infect and kill certain cancer cells. It can also cause the infected cells to express cell surface CD19
Implementation Method 4
The expression of CD19 renders the cells vunerable to killing by CAR T cells targeted to CD19 ('CD19 CAR T cells')
Implementation Method 5
CD19 CAR T cells, thereby treating cancer in the subject
Data Source
AI summary
An oncolytic poxvirus encoding a truncated human CD19 is used in conjunction with a chimeric antigen receptor to treat solid tumors.